OBJECTIVE： To systematically evaluate the efficacy and safety of Lanqin oral liquid in the treatment of herpangina in children. METHODS： Randomized controlled trials （RCTs） involving Lanqin oral liquid or routine symptomatic treatment combined with Lanqin oral liquid （trial group） versus routine treatment （control group） in the treatment of pediatric herpangina were retrieved  from PubMed， Embase， CBM， CNKI， Wanfang database， VIP database， etc. Meta-analysis was performed by using Rev Man 5.3 software after literature screening， data extraction and quality evaluation with Cochrane system evaluator manual 5.1.0. RESULTS： A total of 11 RCTs were included， involving 1 204 patients. Meta-analysis showed that total response rate [RR＝1.17， 95％CI（1.10， 1.24）， P＜0.000 01]， fade time of herpes [MD＝－2.17， 95％CI（－2.63， －1.72）， P＜0.000 01] and fade time of fever [MD＝－1.52， 95％CI（－1.72， －1.31）， P＜0.000 01] in trial group was significantly higher than in control group. There was no statistical significance in the incidence of ADR between 2 groups [RR＝1.00， 95％CI（0.52， 1.93）， P＝1.00]. Subgroup analysis based on rehydration symptomatic treatment showed that without rehydration， fade time of herpes in trial group was significantly shorter than control group [MD＝－1.64， 95％CI （－2.03， －1.26）， P＜0.000 01]； with rehydration， fade time of herpes in trial group was significantly shorter than control group [MD＝－2.79， 95％CI（－2.97， －2.61），P＜0.000 01]. CONCLUSIONS： Lanqin oral liquid can effectively improve therapeutic efficacy of herpangina patients， effectively shorten fade time of fever and herpes， without increasing the occurrence of ADR.